Navigation Links
NLST data highlight probability of lung cancer overdiagnosis with low-dose CT screening
Date:12/9/2013

Philadelphia, PAData from the National Lung Cancer Screening Trial (NLST)conducted by the American College of Radiology Imaging Network and National Cancer Institute Lung Screening Studyprovided researchers the opportunity to investigate the probability that a cancer detected with screening low-dose computed tomography (LDCT) would not have progressed to become life threatening. The results of this investigation published online today in JAMA Internal Medicine suggest that up to 18 percent of the cancers detected by LDCT may not have progressed enough to affect patient health if left undetected.

"This is another piece of important information that helps us to better understand the benefits and risks of lung cancer screening," says the study's lead author, Edward F. Patz, Jr., M.D., a professor of radiology, and pharmacology and cancer biology at Duke University School of Medicine.

"The NLST provided encouraging data demonstrating that lung cancer screening with CT reduces death from the disease. However, there are inherent risks with any mass screening program, and this paper investigates the probability of overdiagnosismeaning, if some patients never would have been screened for lung cancer, they would never have known they had the disease because it would never have caused symptom."

The specific negative consequences of overdiagnosis described by the authors include unnecessary invasive diagnostic procedures, treatment, morbidity (and mortality in rare cases), follow-up, cost, patient anxiety, and labeling of patients with a disease that otherwise would never have been detected.

Using NLST data, the authors determined an "upper bound to true overdiagnosis rate" because the post-screening follow-up period in NLST may not have been long enough to totally differentiate overdiagnosis from the effects of lead timethe length of time a diagnosis was moved up due to early detection by screening. The probability that any lung cancer (all types and stages) detected by screening with LDCT is an overdiagnosis was reported as 18.5 percent. The probability that an LDCT-detected non-small cell lung cancerby far the most frequently diagnosed lung cancer typerepresents an overdiagnosis was found to be 22 percent. The overdiagnosis rate for bronchioloalveolar lung cancer was 78.9 percent.

Patz explains that the problem clinicians face is not knowing which patients are among the approximate 18 percent who have indolent disease. "Patients with these nonaggressive cancers are treated the same as any other patient with lung cancer, because it is generally not possible to distinguish indolent lesions from more aggressive tumors," says Patz. The authors emphasize the need for better biomarkers and imaging techniques to determine which lung cancers are more or less aggressive so as to optimize patient care and enhance the value of screening programs.

"Overdiagnosis is something we don't commonly think exists in lung cancer as compared with, for example, prostate cancer," says Patz. "Most often, when patients are diagnosed with lung cancer, it's viewed as a fatal disease. However, these data confirm that's not necessarily the case with screening programs, which is important information for clinicians to discuss with their patients."

"The relatively modest rate of overdiagnosis with low-dose CT compared with the overdiagnosis rate projected for other cancer screenings programs, further supports the implementation of lung cancer screening programs. Of course, it's important that we work to further drive down overdiagnosis rates across all screening programs," says Mitchell D. Schnall, M.D., Ph.D., Co-Chair of the ECOG-ACRIN Cancer Research Group and the Radiology Department Chair at the University of Pennsylvania's Perelman School of Medicine.


'/>"/>

Contact: Shawn Farley
PR@acr.org
703-648-8936
American College of Radiology
Source:Eurekalert

Related biology technology :

1. The Zacks Analyst Blog Highlights: Celgene, Biogen, Gilead, Orexigen and Cubist
2. How to Enhance Scientific Intuition in Pharmaceutical R&D: the CBCD Highlights a Revolutionary New Technology
3. Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013
4. Bend Research to Highlight Latest Drug Formulation Technologies
5. Pittcon 2014 Announces Highlights of Annual Waters Symposium
6. The Zacks Analyst Blog Highlights: Eaton, Baxter International, Bio-Rad Laboratories, INSYS Therapeutics and Boston Scientific
7. SCAI Paper Highlights Best Practices For Diagnosing And Treating Blocked Arteries Via The Wrist
8. Apache's New Video Highlights Benefits of Employee Ownership
9. SACHEM Booth #1441 At SEMICON Europa Oct 8-10th, Highlighting Envure Systemâ„¢
10. The Zacks Analyst Blog Highlights: SPDR Health Care Select Sector Fund, SPDR S&P 500, SPDRS&P Biotech ETF, PowerShares S&P SmallCap Health Care Portfolio and PowerShares Dynamic Biotechnology & Genome Portfolio
11. Cellular Biomedicine Group Reports Second Quarter and First Half 2013 Financial Results and Business Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... 20, 2017 Stock-Callers.com explores the ... influenced the most recent performances of select equities. In ... RGLS ), Abeona Therapeutics Inc. (NASDAQ: ... ), and Sage Therapeutics Inc. (NASDAQ: SAGE ... View Research, global Biotech market size is expected to reach $604.40 billion by ...
(Date:1/19/2017)... Jan 19, 2017 Research and Markets has ... Technology, Biomolecules, Cancer Type, Application - Global Opportunity Analysis and Industry ... ... the global market is projected to reach $15,737 million by 2022 ... 2016 to 2022. Omic technologies segment accounted for ...
(Date:1/19/2017)... Research and Markets ... announced the addition of the "Implantable Biomaterials Market ... report to their offering. Report Highlights: ... analysis on current and future market trends to identify the investment opportunities ... the base numbers Key market trends across the business ...
(Date:1/19/2017)... 19, 2017  ArmaGen, Inc., today announced that ... as chief executive officer, as well as a ... to ArmaGen more than 17 years of executive ... of biotherapeutics and pharmaceuticals. "Mathias ... experience and skillset necessary to lead ArmaGen to ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, Inc. ... genomics technology company, announced today that on December 13, ... Department of The Nasdaq Stock Market LLC which acknowledged ... price of WaferGen,s common stock had been at $1.00 ... has regained compliance with Listing Rule 5550(a)(2) of the ...
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in ... biometrics market" The mobile biometrics market is expected to ... 49.33 billion by 2022, at a CAGR of 29.3% ... factors such as the growing demand for smart devices, ... transactions. "Software component is expected to grow ...
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition Market ... Application Area, End User, And Region - Global Forecast to 2021", published by ... 2016 to USD 36.07 Billion by 2021, at a Compound Annual Growth Rate ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):